Lilly directed to pay $176.5m by US court to Teva in migraine drug patent case
In the trial, the jury found that Lilly's migraine drug Emgality infringed three Teva patents and the infringements…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Nov 22
In the trial, the jury found that Lilly's migraine drug Emgality infringed three Teva patents and the infringements…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Nov 22
Sanofi will make upfront and target nomination fees totalling up to $21.5m for identifying, synthesising and advancing up…
09 Nov 22
The approval was based on better survival results of Libtayo plus chemotherapy in comparison to chemotherapy alone in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 22
Oyster Point owns the FDA-approved Tyrvaya, which is used for the treatment of dry eye disease, while Famy…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 22
Beyfortus is a long-acting antibody, indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Nov 22
The Breakthrough Therapy Designation was granted based on updated data from the Phase 2 MagnetisMM-3 study, in which…
03 Nov 22
The current FDA approval expands Vemlidy’s previous indication as a once-daily therapy to treat chronic HBV infection in…
03 Nov 22
The new facility will support the North American growth of Kinder Bueno, which Ferrero launched in the market in…
03 Nov 22
Exelixis expects each of the licenced antibodies to have the potential to be turned into an ADC or…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Nov 22
As per the terms of the deal, CSL Seqirus will pay Arcturus $200m upfront and an additional $1.3bn…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates